Showing 1 posts of 1 posts found.
Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation